Thank you @noobietrader. Some valid points. Appreciate your...

First 453 Last

Share
Profile

Follow
Chev007

260 Posts.

3

10/08/17

22:31

Post #: 26429826
Share

Originally posted by noobietrader ↑

I think great news is subjective to each individual.

Business is growing based on the last few quarterlies. Is it growing enough? Again, don't know without any forecasts. I also made a comment earlier on the initial 205k income figure. Based on that and the last quarterly received being 211, that's an increase of only 6k in three quarters when the clients have more than doubled

Direction/vision: there's definitely a target here, the milestones. The strategy has changed since last year, and that's fine - no point chasing something that's not getting you anywhere. the acquisitions is quite interesting. This seems to me to be a desperate move to hit the milestones. Acquisitions has been spoken about and the feel that I got was that it was only ever if they needed to take out competition or something similar to control the market, whereas the last couple of communications it feels as though it's to help achieve milestones rather than natural progression.

Resources: I always felt like they were one specialised person short. Tony may be the answer to this (on paper he looks like the right person/experience), time will tell.

I'm not so fussed about announcements and spelling etc, but my point was more so about the messages coming out from the company. Say one thing but are doing something else etc.

Tough day today and it's very disappointing. My messages aren't to rub it into anyone as almost everyone would be down - purely discussing the stock.

I've always said I think there is heaps of potential there. Whether they can pull it off or not is another story - time will tell.

Expand

Thank you @noobietrader. Some valid points. Appreciate your point of view : )

Good Fortune!

IAM Price at posting: 1.8¢ Sentiment: Buy Disclosure: Held
3 Upvote

0 Great analysis

Reply

Top Stories

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

CHM

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

There are more pages in this discussion • 12 more messages in this thread...

First 453 Last

Add CF1 (ASX) to my watchlist

(20min delay)
Last 2.2¢		Change 0.000(0.00%)		Mkt cap ! $12.58M

Open	High	Low	Value	Volume
0.0¢	0.0¢	0.0¢	$0	0

Buyers (Bids)

No.	Vol.	Price($)
1	91	2.2¢

Sellers (Offers)

Price($)	Vol.	No.
2.3¢	300000	1

View Market Depth

No.	Vol.	Price($)
1	91	0.022
1	491617	0.020
1	200000	0.019
3	1434231	0.018
1	1000000	0.017

Price($)	Vol.	No.
0.023	300000	1
0.024	125000	1
0.025	170043	1
0.026	64744	1
0.028	483161	1

Last trade - 10.02am 07/10/2024 (20 minute delay)

CF1 (ASX) Chart

Day chart unavailable

Thank you @noobietrader. Some valid points. Appreciate your...

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Thank you @noobietrader. Some valid points. Appreciate your...

Top Stories

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News